Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-K20
- Development stage
- Preclinical
- Lead developer
- Duke University
- Modality
- Gene Therapies
- Administration
- Intra-arterial, Intravenous
01
Overview
AAV-K20 (also known as AAV.k20) is an engineered adeno-associated virus (AAV) capsid variant derived from AAV9. Developed by researchers at Duke University, AAV-K20 was engineered via directed evolution and cross-species cycling of capsid libraries (including 7-mer peptide insertion in the variable region IV of the AAV9 capsid) to exhibit enhanced tropism and transduction efficiency for kidney tissues, particularly proximal tubule (PT) epithelial cells. It is being investigated as a gene delivery vector for the treatment of genetic kidney diseases, inherited kidney tubulopathies, and chronic kidney disease (CKD), as well as for applications in kidney transplantation.
Beyond the preview
Go deeper on AAV-K20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV-K20.